To evaluate the prospect of using collateral sensitivity drugs in the treatment of drug resistant cancers, it was of interest to identify non-toxic and clinically approved drugs that can trigger P-gp-dependent collateral sensitivity. The gene discussed is PGP; the disease is cancer.